Impact MRSA -PCR on Patient Management
- Conditions
- MRSA Bacteremia
- Registration Number
- NCT03096405
- Lead Sponsor
- Fondation Hôpital Saint-Joseph
- Brief Summary
Staphylococcus aureus represents one of the most met germs, with Escherichia coli, during bacteremia. Microbiologist distinguish at aureus S. two profiles of resistance in beta-lactamines: S. aureus sensitive to the methicillin ( SASM) and the S. aureus resistant to the methicillin ( SARM).
With the implementation of the MALDI-TOF, it is now possible to identify the origin responsible of the bacteremia the day of the positivity of the hemoculture ( J0) and to set up a treatment with adapted antibiotic, which, in the case of a sepsis to aureus S., is the vancomycine. Ye it was demonstrated, that the use of the vancomycine on the SASM increased the average duration of stay and a more important rate of relapse.
The PCR SARM was organized in the GHPSJ in 2014. It allows from the day of the positivity of the hemoculture ( J0), to determine the phenotype of resistance of S. aureus.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- Hemoculture positive to Staphylococcus Aureus Methicillin Sensitive
- Positive test to Staphylococcus Aureus Methicillin Sensitive but not hospitalized.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adaptation duration of antibiotherapy 24 hours
- Secondary Outcome Measures
Name Time Method average duration of hospitalization day 30 Mortality Day 30
Trial Locations
- Locations (1)
Groupe Hospitalier Paris Saint Joseph
🇫🇷Paris, Ile-de-France, France